SCHEDULE 13G/A: FMR LLC and Abigail P. Johnson Disclose 4.9% Passive Stake in Turnstone Biologics Corp.

FMR LLC and its affiliate Abigail P. Johnson have filed an amended Schedule 13G, reporting a passive beneficial ownership of 4.9% in Turnstone Biologics Corp.'s common stock as of March 31, 2025.

Summary

• FMR LLC and Abigail P. Johnson, as reporting persons, collectively beneficially own 1,133,987 shares of Turnstone Biologics Corp.'s common stock.
• This ownership represents 4.9% of the total outstanding common stock of Turnstone Biologics Corp.
• The filing is an Amendment No. 3 to a Schedule 13G, indicating previous ownership disclosures.
• FMR LLC holds sole voting and dispositive power over all 1,133,987 shares.
• Abigail P. Johnson holds sole dispositive power over the same 1,133,987 shares but no sole voting power.
• The securities were acquired and are held for investment purposes and not with the intent to change or influence the control of Turnstone Biologics Corp.
• The filing was made under Rule 13d-1(b), which is for passive investors.
• IMPRESA MANAGEMENT LLC, classified as an Investment Adviser (IA), is a relevant entity that beneficially owns shares as part of the FMR Reporters group.

Sentiment

Score: 5

Explanation: This is a neutral, factual ownership disclosure filing (Schedule 13G) and does not contain information that would typically influence sentiment positively or negatively regarding the issuer's performance or prospects.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11."

Industry Context

This filing is a routine ownership disclosure for a biotechnology company, indicating a significant but passive investment by a major asset manager. It does not provide specific insights into Turnstone Biologics Corp.'s operational performance or industry position, but rather reflects an investment decision by FMR LLC within the broader biotech sector.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional investor's passive stake, confirming no immediate intent to influence company control.
• Management: Confirms that a major investor is not seeking to influence management or strategic direction at this time.

Key Dates

Keywords

Turnstone Biologics Corp., FMR LLC, Abigail P. Johnson, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Passive Investment, Biologics, Biotechnology